Investigation of <i>ITGB3</i> Heterogeneity to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer
HER2-positive breast cancer has an aggressive tumour progression among breast cancers characterized by the overexpression of HER2. Trastuzumab is an FDA-approved drug and has significantly improved outcomes for patients; however, drug resistance remains a major challenge. Tumour heterogeneity, descr...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-7737/14/1/9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|